Ahammune Biosciences raises $5 million to fund novel vitiligo therapy
The funding will enable the company in conducting Phase II human clinical trials for its potential drug candidate for ...
Your Story15h
Ahammune Biosciences bags $5M in Series A funding
The biotech startup will use the funds to assist its Phase II human clinical trials for its drug candidate for vitiligo.
entrackr13h
Biotech startup Ahammune Biosciences raises $5 Mn led by pi Ventures
Biotech startup Ahammune Biosciences has raised $5 million in Series A funding round led by pi Ventures. The round also ...
Biotech Startup Ahammune Biosciences Raises $5 Million in Series A Funding
Ahammune Biosciences, a clinical-stage therapeutics company focused on developing new treatments for skin diseases, has ...
VCCircle6h
Ahammune Biosciences, The Health Factory, two others raise early-stage cheques
Clinical stage therapeutics startup Ahammune Biosciences, bread brand The Health Factory, proptech startup Flent and ...
The Citizen15h
Albinism Society of South Africa fundraiser celebrates uniqueness
Celebrating the success of the Albinism Society of South Africa (ASSA) fundraising event held at Birchwood Hotel recently are ...
AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis
Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...